Preferred Label : Elenestinib;
NCIt synonyms : D816V-mutant KIT Inhibitor BLU-263; KIT D816V Mutant-selective Inhibitor BLU-263;
NCIt definition : An orally bioavailable protein tyrosine kinase inhibitor of the mutated form of the
tumor-associated antigen (TAA) mast/stem cell factor receptor c-Kit (SCFR), D816V,
with potential antineoplastic activity. Upon oral administration, elenestinib binds
to and inhibits the specific c-Kit mutant D816V. This may result in an inhibition
of cell proliferation in mast cells that overexpress this c-Kit mutation. D816V, a
mutation in which the amino acid asparagine aspartic acid at position 816 in the mast/stem
cell growth factor receptor Kit protein is replaced by valine, may drive mastocytosis
and other mast cell disorders.;
UNII : 6FBM4CP6RK;
CAS number : 2505078-08-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2505078-08-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : BLU-263; BLU 263;
NCI Metathesaurus CUI : CL1663468;
Origin ID : C180833;
UMLS CUI : C5783439;
Semantic type(s)
- concept_is_in_subset
- has_target
